Article
Cardiac & Cardiovascular Systems
Elisangela C. P. Lopes, Layde R. Paim, Luis F. R. S. Carvalho-Romano, Edmilson R. Marques, Eduarda O. Z. Minin, Camila F. L. Vegian, Jose A. Pio-Magalhaes, Licio A. Velloso, Otavio R. Coelho-Filho, Andrei C. Sposito, Jose R. Matos-Souza, Wilson Nadruz, Roberto Schreiber
Summary: This study evaluated the relationship between circulating miRNAs and left ventricular hypertrophy (LVH) in hypertensive patients. The results showed that miR-145-5p, miR-451, and let7c were independently associated with LVH and left ventricular mass index. These miRNAs were also found to regulate genes and pathways related to cardiac remodeling.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Sukka Santosh Reddy, Heena Agarwal, Anant Jaiswal, Kumaravelu Jagavelu, Madhu Dikshit, Manoj Kumar Barthwal
Summary: The study found that macrophage p47phox plays a role in hypertensive cardiac remodeling, with its deficiency potentially leading to worsened cardiac dysfunction, hypertrophy, and increased interstitial fibrosis. Further experiments revealed elevated expression of M2 macrophage markers in KO mice, suggesting a restrictive role of p47phox in anti-inflammatory signaling during cardiac remodeling.
FREE RADICAL BIOLOGY AND MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Valeria R. Martinez, Augusto Martins Lima, Nikolaous Stergiopulos, Jorge O. Velez Rueda, Maria S. Islas, Mercedes Griera, Laura Calleros, Manuel Rodriguez Puyol, Carolina Jaquenod de Giusti, Enrique L. Portiansky, Evelina G. Ferrer, Veronica De Giusti, Patricia A. M. Williams
Summary: Hypertension is the main cause of left ventricular hypertrophy and can lead to heart failure. Candesartan, an angiotensin receptor antagonist, is commonly used for hypertension treatment. Our study focused on the structural modification of candesartan using zinc (ZnCand) to enhance its pharmacological properties. The results showed that ZnCand exhibited stronger interaction with the AT1 receptor, reducing oxidative stress and intracellular calcium flux. Additionally, in vivo experiments demonstrated that ZnCand effectively reduced systolic blood pressure and heart hypertrophy in SHR rats, while restoring the redox status.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2023)
Article
Nutrition & Dietetics
Yoichi Sunagawa, Masafumi Funamoto, Kana Shimizu, Satoshi Shimizu, Nurmila Sari, Yasufumi Katanasaka, Yusuke Miyazaki, Hideaki Kakeya, Koji Hasegawa, Tatsuya Morimoto
Summary: Curcumin, a p300 histone acetyltransferase (HAT) inhibitor, has been found to prevent hypertension-induced left ventricular hypertrophy (LVH) development, without affecting blood pressure and systolic function.
Article
Cardiac & Cardiovascular Systems
Hyeok-Hee Lee, Hokyou Lee, So Mi Jemma Cho, Dong-Wook Kim, Sungha Park, Hyeon Chang Kim
Summary: This study found that maintaining blood pressure at SBP <130 mm Hg and DBP <80 mm Hg was associated with the lowest risk for cardiovascular events in adults with hypertension and LVH. Further randomized trials are needed to establish optimal blood pressure-lowering strategies for these patients.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Emilio Nardi, Giuseppe Mule, Antonina Giammanco, Alessandro Mattina, Giulio Geraci, Chiara Nardi, Maurizio Averna
Summary: This study assessed the prevalence of LVH in hypertensive patients with stage 2-5 CKD, finding a high prevalence of LVH, especially in advanced CKD stages. The association between LVH and CKD was confirmed, with negative effects on diastolic function.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
(2021)
Article
Medicine, General & Internal
Anett Apitz, Thenral Socrates, Thilo Burkard, Michael Mayr, Annina S. Vischer
Summary: The study aimed to investigate the prevalence of left ventricular hypertrophy (LVH) in patients with arterial hypertension (AHT) and describe patients with severe LVH. The results showed that over half of the AHT patients (52.5%) had abnormal left ventricular geometry, and 7.3% had severe LVH. Patients with severe LVH were more likely to be male, older, have uncontrolled blood pressure (especially during sleep), receive multiple antihypertensive treatments, and have comorbidities compared to those with normal left ventricular geometry.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Su-Hai Fei, Zhen-Feng Liu, Hai-Ning Xie, Jia-Ni Tong, Zheng-Mei Fang, Yan Chen, Ying-Shui Yao
Summary: In this study, miRNA's diagnostic value for hypertension with left ventricular hypertrophy was evaluated through meta-analysis. The results showed that miRNA has high sensitivity and specificity in this diagnosis, making it a better biological marker.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Endocrinology & Metabolism
Monika Drozdz, Anna Moczulska, Andrzej Rudzinski, Dorota Drozdz
Summary: This study aimed to identify the most significant risk factors of left ventricular hypertrophy (LVH) in children with chronic kidney disease (CKD). The results showed that metabolic syndrome, hypertension, and CKD stage were the most important risk factors for LVH.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Ljuba Bacharova, Marta Kollarova, Branislav Bezak, Allan Bohm
Summary: Left ventricular hypertrophy (LVH) refers to the complex rebuilding of the left ventricle, which can lead to heart failure and life-threatening ventricular arrhythmias. Imaging methods such as echocardiography and cardiac magnetic resonance can diagnose the increase in left ventricle size, while other methods can evaluate the functional status and underlying processes of LVH. Molecular and genetic biomarkers offer insights and potential for targeted therapy. This review summarizes the main biomarkers used in LVH evaluation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Pharmacology & Pharmacy
Chunfang Xu, Ziying Zhao, Wang Yuan, Zhao Fengping, Yan Zhiqiang, Zhang Xiaoqin
Summary: The study found that allisartan lowers blood pressure and improves left ventricular remodeling by increasing the expression of Kv1.5 channels.
CLINICAL AND EXPERIMENTAL HYPERTENSION
(2022)
Article
Peripheral Vascular Disease
Cesare Cuspidi, Marijana Tadic, Carla Sala, Fosca Quarti-Trevano, Elisa Gherbesi, Giuseppe Mancia, Guido Grassi
Summary: This systematic meta-analysis of echocardiographic studies on primary aldosteronism patients after adrenalectomy found that the procedure can lead to a reduction in left ventricular hypertrophy and an improvement in left ventricular structure and geometry.
JOURNAL OF HYPERTENSION
(2021)
Review
Cardiac & Cardiovascular Systems
Flavio D'Ascenzi, Caterina Fiorentini, Francesca Anselmi, Sergio Mondillo
Summary: Athletes' hearts undergo remodeling due to exercise, but this can sometimes be mistaken for pathological hypertrophy seen in cardiac disorders like hypertension. Differentiating between athlete's heart and hypertensive heart disease can be challenging due to similar changes in left ventricular mass and wall thickness caused by training.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Ping Guan, Jun Gu, Zhi-ping Song, Chang-qian Wang, Wei Hu, Jun-feng Zhang
Summary: This study found that a quarter of patients with hypertensive left ventricular hypertrophy and HFpEF progress to systolic dysfunction during a 5-year follow-up, with poor clinical outcomes. Beta-blocker therapy may play a protective role in preserving LVEF, and the transition of LV geometry is uncommon.
Article
Cardiac & Cardiovascular Systems
Angelo de la Rosa, Maulin Shah, Takahiro Shiota, Robert Siegel, Florian Rader
Summary: Compared to hypertensive LVH, gene-positive HCM is characterized by more severe diastolic dysfunction and larger LA size. Gene-positive HCM patients with concomitant HTN exhibit greater LV mass, more severe LVH, and more abnormal GLS, suggesting that HTN may negatively impact the progression of myocardial dysfunction in genetic HCM. LVH out-of-proportion to pressure burden in HTN patients should raise suspicion of underlying genetic HCM.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING
(2022)